Condition: Hidradenitis Suppurativa (HS) · Sponsor: Novartis Pharmaceuticals
This is a post-approval commitment study to evaluate efficacy, and safety of two dosing regimens of secukinumab (AIN457), 300 mg every four weeks (Q4W) and every two weeks (Q2W), in Chinese adult patients with moderate to severe hidradenitis suppurativa (HS).
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · + 1-888-669-6682 · novartis.email@novartis.com
Novartis Pharmaceuticals
Always discuss trial participation with your own doctor first.
| Novartis Investigative Site | Hangzhou, Zhejiang, China | Recruiting |
| Novartis Investigative Site | Ningbo, Zhejiang, China | Recruiting |
| Novartis Investigative Site | Wenzhou, Zhejiang, China | Recruiting |
| Novartis Investigative Site | Beijing, China | Recruiting |
| Novartis Investigative Site | Beijing, China | Recruiting |
| Novartis Investigative Site | Shanghai, China | Recruiting |
| Novartis Investigative Site | Tianjin, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07489573